| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DSE |
| Uniprot No | Q9UL01 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-958aa |
| 氨基酸序列 | MRTHTRGAPSVFFIYLLCFVSAYITDENPEVMIPFTNANYDSHPMLYFSRAEVAELQLRAASSHEHIAARLTEAVHTMLSSPLEYLPPWDPKDYSARWNEIFGNNLGALAMFCVLYPENIEARDMAKDYMERMAAQPSWLVKDAPWDEVPLAHSLVGFATAYDFLYNYLSKTQQEKFLEVIANASGYMYETSYRRGWGFQYLHNHQPTNCMALLTGSLVLMNQGYLQEAYLWTKQVLTIMEKSLVLLREVTDGSLYEGVAYGSYTTRSLFQYMFLVQRHFNINHFGHPWLKQHFAFMYRTILPGFQRTVAIADSNYNWFYGPESQLVFLDKFVMRNGSGNWLADQIRRNRVVEGPGTPSKGQRWCTLHTEFLWYDGSLKSVPPPDFGTPTLHYFEDWGVVTYGSALPAEINRSFLSFKSGKLGGRAIYDIVHRNKYKDWIKGWRNFNAGHEHPDQNSFTFAPNGVPFITEALYGPKYTFFNNVLMFSPAVSKSCFSPWVGQVTEDCSSKWSKYKHDLAASCQGRVVAAEEKNGVVFIRGEGVGAYNPQLNLKNVQRNLILLHPQLLLLVDQIHLGEESPLETAASFFHNVDVPFEETVVDGVHGAFIRQRDGLYKMYWMDDTGYSEKATFASVTYPRGYPYNGTNYVNVTMHLRSPITRAAYLFIGPSIDVQSFTVHGDSQQLDVFIATSKHAYATYLWTGEATGQSAFAQVIADRHKILFDRNSAIKSSIVPEVKDYAAIVEQNLQHFKPVFQLLEKQILSRVRNTASFRKTAERLLRFSDKRQTEEAIDRIFAISQQQQQQSKSKKNRRAGKRYKFVDAVPDIFAQIEVNEKKIRQKAQILAQKELPIDEDEEMKDLLDFADVTYEKHKNGGLIKGRFGQARMVTTTHSRAPSLSASYTRLFLILNIAIFFVMLAMQLTYFQRAQSLHGQRCLYAVLLIDSCILLWLYSSCSQSQC |
| 预测分子量 | 109,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DSE(重组蛋白表达与优化)领域的3篇代表性参考文献示例(注：内容为模拟虚构，供参考)：
1. **《Optimization of Recombinant DSE Protein Expression in E. coli》**
- 作者：Zhang, L. et al.
- 摘要：本研究通过优化大肠杆菌表达系统的培养条件(如温度、诱导剂浓度)，显著提高了DSE重组蛋白的产量，并解决了包涵体形成问题，为规模化生产提供了可行方案。
2. **《DSE Recombinant Protein in Cancer Immunotherapy: Mechanisms and Applications》**
- 作者：Smith, J. & Patel, R.
- 摘要：探讨DSE重组蛋白作为肿瘤抗原递呈载体的作用，通过体外实验证明其可激活T细胞免疫应答，为癌症疫苗开发提供了新思路。
3. **《High-Yield Purification of DSE Fusion Protein Using Affinity Chromatography》**
- 作者：Kim, H. et al.
- 摘要：开发了一种基于组氨酸标签的亲和层析纯化工艺，实现了DSE重组蛋白的高效纯化(纯度>95%)，并验证了其生物活性在体外模型中的稳定性。
---
**说明**：
- DSE(Downstream Effector Protein)常指特定功能的信号通路相关蛋白，实际文献需根据具体研究目标检索。
- 真实文献可通过PubMed、Web of Science等平台，以关键词“recombinant protein expression optimization”、“DSE protein application”查询近年高被引论文。
- 如需实际文献推荐，请提供更具体的蛋白名称或研究背景。
DSE (Drug Substance Entity) recombinant proteins are engineered proteins produced through genetic modification techniques, primarily for applications in therapeutics, diagnostics, and biomedical research. These proteins are designed by inserting target gene sequences into host systems (e.g., bacterial, yeast, or mammalian cells) to enable large-scale production of specific protein molecules with defined functions. The development of DSE recombinant proteins aligns with advancements in genetic engineering, particularly since the 1980s, when recombinant DNA technology became a cornerstone of biopharmaceutical innovation.
DSE recombinant proteins are pivotal in addressing diseases with complex mechanisms, such as cancer, autoimmune disorders, and infectious diseases. For example, monoclonal antibodies, cytokines, and enzyme replacements often utilize this platform due to their high specificity and reduced immunogenicity compared to traditional small-molecule drugs. The production process involves rigorous optimization of expression systems to ensure proper folding, post-translational modifications (e.g., glycosylation), and scalability. Mammalian cell lines like CHO (Chinese Hamster Ovary) are frequently employed for their ability to perform human-like protein modifications.
Quality control is critical, requiring stringent characterization via techniques like mass spectrometry, HPLC, and bioassays to verify purity, stability, and activity. Regulatory frameworks (e.g., FDA, EMA) mandate compliance with Good Manufacturing Practices (GMP) to ensure clinical safety and efficacy.
Recent trends focus on enhancing yield and cost-effectiveness through synthetic biology and AI-driven protein design. Challenges remain, including host cell protein contamination and aggregation during production. Despite this, DSE recombinant proteins continue to revolutionize personalized medicine and biologics, with growing pipelines in gene therapies, vaccines, and targeted treatments. Their versatility and adaptability position them as essential tools in modern biotechnology and healthcare.
×
